InsidersTradesSigma
Better Therapeutics, Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the Better Therapeutics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Better Therapeutics, Inc. has logged 74 insider filings. Market capitalisation: €5k. The latest transaction was reported on 13 February 2024 (Attribution). Among the most active insiders: Armanino Andrew J.. Every trade is accessible without an account.
74
Insider Decl.
0
Thresholds
€4m
45 ops.
Buy Volume
·
0 ops.
Sell Volume
52Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 13 February 2024
Declarations74 total
839,895 shares@ US$0.19056.6% of flowCommon StockSEC:0000950170-24-014898:0
1,471,453 shares@ US$0.169910.1% of flowCommon StockSEC:0000950170-24-003637:0
3,750 shares0Common StockSEC:0000950170-23-071961:0
25,362 shares0Common StockSEC:0000950170-23-071959:0
3,750 shares0Common StockSEC:0000950170-23-071958:0
62,500 shares0Common StockSEC:0000950170-23-071939:0
3,750 shares0Common StockSEC:0000950170-23-071942:0
25,362 shares0Common StockSEC:0000950170-23-071936:0
3,750 shares0Common StockSEC:0000950170-23-071963:0
3,750 shares0Common StockSEC:0000950170-23-071957:0
3,587 shares0Common StockSEC:0000950170-23-071956:0
3,750 shares0Common StockSEC:0000950170-23-071960:0
1,233,045 shares@ US$0.729936.2% of flowCommon StockSEC:0000950170-23-035685:0
Ideal exit: 22 Apr 2024 (T+270)
685,025 shares@ US$0.729949.3% of flowCommon StockSEC:0000950170-23-035679:0
Ideal exit: 22 Apr 2024 (T+270)
54,802 shares@ US$0.7299100.0% of flowCommon StockSEC:0000950170-23-035684:0
Ideal exit: 22 Apr 2024 (T+270)
34,251 shares@ US$0.729965.0% of flowCommon StockSEC:0000950170-23-035681:0
Ideal exit: 22 Apr 2024 (T+270)
274,010 shares@ US$0.729919.0% of flowCommon StockSEC:0000950170-23-035682:0
Ideal exit: 22 Apr 2024 (T+270)
137,005 shares@ US$0.729924.0% of flowCommon StockSEC:0000950170-23-035680:0
Ideal exit: 22 Apr 2024 (T+270)
600 shares@ US$0.86721.4% of flowCommon StockSEC:0000950170-23-022874:0
Ideal exit: 10 Feb 2024 (T+270)
101,450 shares0Common StockSEC:0000950170-23-013896:0
54,000 shares0Common StockSEC:0000950170-23-013898:0
101,450 shares0Common StockSEC:0000950170-23-013897:0
1,333,333 shares@ US$0.82544.7% of flowCommon StockSEC:0000899243-23-011231:0
Ideal exit: 5 Jan 2024 (T+270)
242,424 shares@ US$0.82548.4% of flowCommon StockSEC:0000899243-23-011189:0
Ideal exit: 5 Jan 2024 (T+270)
303,030 shares@ US$0.82523.9% of flowCommon StockSEC:0000899243-23-011187:0
Ideal exit: 5 Jan 2024 (T+270)
25 of 74 declarations
About Better Therapeutics, Inc.
Better Therapeutics, Inc. (ticker: BTTX) is a U.S.-based digital health company that has been listed on the NASDAQ market in the United States. The company was founded in 2015, originally as Nutrition Development Group LLC, later renamed Farewell LLC and then Better Therapeutics LLC, before becoming a Delaware corporation in 2020. Its headquarters are in San Francisco, California. Better Therapeutics develops prescription digital therapeutics (PDTs): regulated, software-based therapies designed to deliver behavioral intervention through a mobile application and support durable changes in patient behavior. The company’s core focus has been cardiometabolic disease, a large and clinically important area that includes conditions such as type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, NASH, and chronic kidney disease. Its business model is built around a proprietary PDT platform and a therapeutic approach based on cognitive behavioral therapy. The best-known product associated with the company is AspyreRx, a prescription digital therapy for type 2 diabetes that has received FDA authorization. More broadly, Better Therapeutics has positioned itself as a technology-enabled healthcare company targeting the root causes of chronic disease rather than only treating symptoms. From a competitive standpoint, Better Therapeutics operates in an early-stage and highly specialized segment at the intersection of software, behavioral medicine, and chronic disease management. Its investment case has historically rested on several differentiators: a drug-free treatment option, delivery through smartphones, the potential to scale more efficiently than traditional care models, and the possibility of improving adherence and outcomes while lowering total healthcare costs. At the same time, the company has faced significant execution risk. Prescription digital therapeutics require clinical validation, regulatory approval, payer adoption, and commercial traction, all of which can take time and capital. Competition is also rising across digital diabetes care and broader digital therapeutics. Recent public disclosures indicate a stressed corporate situation. In March 2024, Better Therapeutics announced that it would seek strategic alternatives, including a possible wind-down or assignment for the benefit of creditors, and noted that it would be delisted from Nasdaq. That development materially changed the company’s profile and suggests severe financial and operational pressure. For equity investors, the name should therefore be viewed as a distressed, event-driven healthcare situation rather than a conventional growth story. In that context, SEC filings, including insider Form 4 activity, remain important for monitoring governance, ownership changes, and any potential restructuring path.
